Limba
Romanian
Romanian
English|
Amcasertib (BBI503), a first-in-class cancer stemness kinaseinhibitor, is claimed to inhibit Nanogand other CSC pathways by targeting kinases with potential anticancer activity.
| Price | 1.047,00 RON (preturile sunt fara TVA) |
|---|---|
| Description |
Amcasertib (BBI503), a first-in-class cancer stemness kinaseinhibitor, is claimed to inhibit Nanogand other CSC pathways by targeting kinases with potential anticancer activity. |
